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Mutations in genes encoding components of the immune system cause primary immuno-
deﬁciencies. Here, we study a patient with recurrent atypical mycobacterial infection and
early-onset metastatic bladder carcinoma. Exome sequencing identiﬁed two homozygous
missense germline mutations, P733L and P832S, in the JAK1 protein that mediates signalling
from multiple cytokine receptors. Cells from this patient exhibit reduced JAK1 and STAT
phosphorylation following cytokine stimulations, reduced induction of expression of inter-
feron-regulated genes and dysregulated cytokine production; which are indicative of signalling
defects in multiple immune response pathways including Interferon-g production. Recon-
stitution experiments in the JAK1-deﬁcient cells demonstrate that the impaired JAK1 function
is mainly attributable to the effect of the P733L mutation. Further analyses of the mutant
protein reveal a phosphorylation-independent role of JAK1 in signal transduction. These
ﬁndings clarify JAK1 signalling mechanisms and demonstrate a critical function of JAK1 in
protection against mycobacterial infection and possibly the immunological surveillance of
cancer.
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P
rimary immunodeﬁciencies (PIDs) are genetic disorders
that cause immune dysfunction and predisposition
to infection. Selective susceptibility to weakly virulent
mycobacteria, such as M. bovis Bacillus Calmette-Guerin vaccine
or environmental mycobacteria species, is a genetically hetero-
geneous group of rare PIDs so far associated with mutations
in nine genes (IFNGR1, IFNGR2, IL12B, IL12RB1, STAT1,
ISG15, IRF8, IKBKG and CYBB)1. These mutations impair
the production of or the response to a cytokine Interferon-g
(IFN-g), either directly or indirectly, indicating that the IFN-g
pathway is critical for the conﬁnement of mycobacterial
infection2. Nevertheless, genetic aetiology in approximately
half of patients with Mendelian susceptibility to mycobacterial
diseases remains unknown3.
IFN-g is a type II interferon that binds to the IFN-g receptor,
a heterodimer encoded by genes IFNGR1 and IFNGR2. Stimula-
tion of the IFN-g receptor results in the downstream activation
of two Janus kinases: JAK1 and JAK2. Upon activation, JAKs
trans-phosphorylate each other at tyrosines within the kinase
domain and phosphorylate the cytoplasmic tail of the receptor4.
This allows recruitment of the Signal Transducer and Activator
of Transcription 1 (STAT1) protein, which in turn is phospho-
rylated, forms homodimers, relocates to the nucleus, binds
the Gamma Activated Sequences in the genome and drives
the expression of genes implicated in cellular immunity, inclu-
ding antigen processing and presentation and activation
of microbicidal effector functions. Intracellular signalling of
type I interferons, for example, IFN-a and IFN-b, is mediated
by the Interferon-a receptor encoded by IFNAR1 and IFNAR2.
The receptor interacts with Janus kinases JAK1 and TYK2,
leading to phosphorylation of STAT1 and STAT2 proteins, which
then form a heterodimer that translocates to the nucleus, forms a
complex with Interferon Regulatory Factor 9 and induces the
expression of the interferon-stimulated genes5. Multiple other
cytokine receptors also signal through combinations of four
JAKs and seven STAT proteins, for example, JAK1 is also used
in signalling by IL-2, IL-4, IL-7, IL-9, IL-15, IL-21, IL-27, IL-6
family cytokines and IL-10 family cytokines4. To date, germline
mutations in two out of the four known Janus kinases, JAK3
and TYK2, have been found in PID patients6–9. Somatic
mutations in JAK2 have also been shown to cause clonal
myeloproliferative disorders, for example, polycythemia vera
and idiopathic erythrocytosis10,11, whereas somatic JAK1
mutations have been associated with gynaecologic cancers12.
Here, we report the identiﬁcation of germline JAK1 mutations
that result in a functional JAK1 deﬁciency associated
with susceptibility to atypical mycobacterial infection and early-
onset bladder carcinoma. Furthermore, detailed analyses of the
mutant protein reveal phosphorylation-independent mechanism
of JAK1 in signal transduction.
Results
Immunodeﬁciency with susceptibility to mycobacteria.
We studied a 22-year-old male of Pakistani descent, the last
of four children born to a consanguineous marriage of
ﬁrst cousins (Fig. 1a). The patient presented to paediatric
immunology at the age of 3 years with a history of global
developmental delay and recurrent ear and chest infections that
started during the ﬁrst year of life and required multiple hospital
admissions. The patient had received childhood vaccines—
including Bacillus Calmette-Guerin vaccine at birth—and
had normal-course chicken pox at age 3 with one subsequent
episode of shingles. During examination, a skeletal survey
demonstrated lytic and sclerotic lesions affecting long bones,
vertebrae and facial bones. The patient also developed cervical
lymphadenopathy. Bone biopsy was unremarkable, lymph
node biopsy reactive and no pathogen was cultured from
either tissue. Considering that these features were associated
with failure to thrive, raised erythrocyte sedimentation rate (ESR)
(70–90mmper hr), elevated polyclonal IgG (25–30 g l 1), pla-
telets (600–700 109 l 1) and white cell count (20–
25 109 l 1), he was further investigated for infection. Myco-
bacterial skin tests for Mycobacterium avium and Mycobacterium
intracellulare were negative, but Mycobacterium tuberculosis
(Mtb), Mycobacterium malmoense and Mycobacterium scroful-
aceum skin tests were all strongly positive. As his relatively
indolent clinical course was not typical for tuberculosis and Mtb
had not been cultured from bone or lymph node, a clinical
diagnosis of systemic atypical mycobacterial infection was made.
He received anti-mycobacterial treatment (Isoniazid, Ethambutol
and Ciproﬂoxacin, as other agents were not tolerated) and his
condition improved over 12 months with catch-up growth (from
3rd to 25th centile), weight gain (25th to 50th centile) and
improvement in ESR, IgG, platelets and white cell count. His
bone X-rays also showed improvement with residual vertebral
collapse, supporting a diagnosis of resolving multifocal osteo-
myelitis caused by mycobacterial infection. The immunology
investigations demonstrated normal numbers of T and B cells,
reduced populations of naive CD4þ and CD8þ T cells
(Table 1) with normal proliferation after phytohemagglutinin
(PHA) stimulation, and mildly reduced responses to Candida and
puriﬁed protein derivative antigens. Total IgG and IgA levels were
increased, whereas IgM level was normal, as were speciﬁc
antibody responses after tetanus, Hib and pneumococcal vacci-
nations. The karyotype, metabolic screen and chromosomal
radio-sensitivity assays were normal.
The patient remained relatively well until the age of 16,
with mild developmental delay and short stature. His IgG levels
remained high and over time IgM levels fell below the normal
range (Table 1) with persistent mild T lymphopenia and impaired
responses to PHA stimulation. Normal CDR3 spectratyping
results in CD4þ and CD8þ T cells were found, with all
TCR Vb families represented with a Gaussian distribution. T-cell
receptor excision circles levels in CD4þ and CD8þ T cells
were normal.
At the age of 16 years the patient presented with unexplained
cardiomyopathy and a raised ESR (20–40mmh 1) and was
found to have a mediastinal mass on computed tomography
imaging. Biopsies showed pleural and mediastinal ﬁbrosis
with patches of macrophage inﬁltration in lung tissue. No
granulomas were seen and Quantiferon TB Gold test was
negative. Mycobacterium gordonae was isolated from a single
sputum sample, but its relevance remained unclear. In view of his
previous history he received empiric treatment for atypical
mycobacteria (Rifampicin and Ethambutol, Clarithromycin
and Ciproﬂoxacin) with improvement of ESR, IgG level and
the mass but permanent presumed ﬁbrotic occlusion of the
right pulmonary vein. He remained on long-term prophylaxis
with Clarithromycin and Ciproﬂoxacin and had no recurrence
or further mycobacterial infections. He had a number of
skin infections, including planar warts restricted to the forehead,
presumed fungal infections of his nails and severe Norwegian
scabies.
At the age of 21 years the patient developed signiﬁcant
anaemia. He had a history of intermittent red blood per
rectum and no recent history of haematuria. Colonoscopy
revealed a large sessile polyp in his rectum, which was
histologically benign without dysplasia. Thickening of the bladder
wall was noted on magnetic resonance imaging and an extensive
fungating tumour was observed on cystoscopy. Biopsies of
the tumour and a supraclavicular lymph node conﬁrmed
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high-grade metastatic transitional cell carcinoma. The patient
received treatment with chemotherapy including cisplatin and
gemcitabine, but died aged 23 years.
Exome sequencing identiﬁes homozygous JAK1 mutations.
As the patient was born to a consanguineous family, we hypo-
thesized that his disease was caused by a recessive Mendelian
mutation and investigated this possibility by whole-exome
sequencing. The exome data contained 18,029 single nucleotide
variants and small insertions/deletions, including 230 very
rare ones that were not observed in the 6,500 NHLBI Exomes13,
1,000 Genomes database (April 2012 data release)14 and
2,500 exomes analysed internally using the same bioinformatics
pipeline. Five of these rare variants were homozygous
(Supplementary Table 1). Of these ﬁve, three were predicted
to be benign, whereas two missense mutations were predicted
to be probably damaging; both were located in the JAK1
gene, leading to amino-acid changes from proline to leucine
(p.P733L) and from proline to serine (p.P832S) (Fig. 1b).
We found no mutations in genes previously associated
with Mendelian susceptibility to mycobacterial disease, or other
genes involved in the JAK-STAT signalling pathways.
We conﬁrmed both JAK1 mutations by Sanger sequencing
(Fig. 1b) and found that unaffected parents and all three
siblings were heterozygous carriers of both mutations (Fig. 1a).
We then designed genotyping assays for both JAK1 mutations,
screened 1,050 healthy subjects representing 51 populations
from around the world15 and found no healthy carriers.
The ExAC database that contains exome data from 4 60,000
subjects had no instance of the p.P733L mutation, whereas
p.P832S was detected in four heterozygous individuals
(frequency¼ 0.000033).
Similarly to other Janus kinases, JAK1 has FERM and
SH2 domains that are responsible for interaction with the
cytokine receptor, the pseudokinase (JH2) domain that regulates
kinase activity, and the kinase (JH1) domain16,17. The proline
residues at JAK1 positions 733 and 832 are located in the
pseudokinase domain (Fig. 1c). They are conserved within the
human Janus kinase family and in JAK1 across species (Supple-
mentary Fig. 1). We visualized both mutations by modelling
JAK1 pseudokinase and kinase domains on the published TYK2
structure18. Although P832S was located far from the kinase
domain, P733L mapped in the b7–b8 loop close to the inter-
domain interface and may affect interaction between the domains
(Fig. 1d). Taken together, these results suggest that the identiﬁed
JAK1 genetic variants, P733L in particular, could be recessive
pathogenic mutations rather than rare neutral polymorphisms.
Multiple affected JAK1-mediated pathways in immune cells. To
test the hypothesis that JAK1 P733L and P832S mutations are
pathogenic, we studied STAT phosphorylation in the patient’s
lymphocytes (Fig. 2a). STAT1 phosphorylation was signiﬁcantly
reduced after IFN-a, IFN-g and IL-27 stimulations. STAT3
phosphorylation was reduced after IL-10—but not IL-6—stimu-
lation. Phosphorylation of STAT4 was reduced after IFN-a
stimulation, as were phosphorylation of STAT5 after IL-2
stimulation and of STAT6 after IL-4 stimulation (Fig. 2a).
Therefore, multiple signalling pathways mediated by JAK1 are
affected in the patient’s immune cells, suggesting a functional
JAK1 deﬁciency.
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Figure 1 | Two JAK1 mutations found in the patient. (a) Patient’s family tree. (b) Sequence chromatograms showing two mutations in the JAK1 gene.
(c) Domain structure of the JAK1 protein. (d) JAK1 pseudokinase (JH2) and kinase (JH1) domains modelled using the published structure of TYK2
pseudokinase and kinase domains (PDB 4OLI). Pro733 and Pro832 are shown in red and green, respectively.
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We then stimulated whole blood from the patient
and measured production of cytokines IFN-g, IL-12, IL-10,
TNF-a and IL-6. In assays normalized for T-cell counts we found
consistently low IFN-g production in response to PHA stimula-
tion and after co-stimulations with PHA/IL-12 or PHA/IFN-a
in comparison with healthy controls (Fig. 2b). However,
upregulation of IFN-g production after co-stimulations with
lipopolysaccharide/interleukin-12 (LPS/IL-12) or LPS/IFN-a
was normal. Also, the patient had low IL-10 production after
PHA stimulation and co-stimulation with PHA/IFN-a (Fig. 2c).
Production of IL-6 and TNF-a was increased after LPS
stimulation (Fig. 2d,e), whereas production of IL-12 was normal
(Fig. 2f). These results indicate that functional JAK1 deﬁciency is
characterized by a broad immune dysregulation.
Impaired phosphorylation of JAK1, partner JAKs and STATs.
To understand how the P733L and P832S mutations affect
JAK1, we next looked at IFN-a and IFN-g signalling in patient’s
primary ﬁbroblasts. We ﬁrst tested the hypothesis that mutations
impact on the stability of the JAK1 protein, affecting, in turn,
its intracellular levels. We measured JAK1 in ﬁbroblasts
derived from the patient or from two healthy subjects
(Supplementary Fig. 2a), and in HEK-239T cells transiently
expressing the wild type JAK1WT, the patient-derived double-
mutant JAK1P733L/P832S or the kinase-dead mutant JAK1K908E
(Supplementary Fig. 2b). The patient-derived variant of JAK1
was expressed at a slightly lower level than the wild-type JAK1.
The JAK pseudokinase domain regulates activity of the kinase
domain. Hence, both engineered and naturally occurring
mutations in the pseudokinase domain of various JAKs, including
known somatic mutations in JAK1, can affect the kinase
activity19–22. To investigate functional effects of the P733L and
P832S mutations, we measured JAK1-mediated activation of
STAT1 and STAT2 proteins in response to stimulation
with cytokines IFN-a and IFN-g. The level of phosphorylation
of JAK1 upon exposure to IFN-a was profoundly reduced in
patient-derived ﬁbroblasts as compared with control cells
(Fig. 3a). Phosphorylation of STAT1 and STAT2 was also
impaired (Fig. 3a). A reduced STAT1 phosphorylation was also
observed upon treatment with IFN-g (Fig. 3b). The induction of
expression of interferon-regulated genes was also lower in
the patient ﬁbroblasts compared with control ﬁbroblasts (Fig. 4
and Supplementary Fig. 3). These data demonstrate that not
only patient’s peripheral blood mononuclear cells, but also
primary ﬁbroblasts show impaired JAK1 functions, leading to
reduced downstream STAT signalling; such ﬁbroblasts therefore
provide a suitable model for the analysis of JAK1 functions.
The JAK1 pseudokinase domain keeps the basal activity of
the kinase in check and mediates the cytokine-inducible
activation of signalling20. The mutations found in the patient
could either affect the level of JAK1 phosphorylation or its onset
or decay, causing delayed or shortened cellular responses. We
studied responses to IFN-a and IFN-g in a time-course
experiment and observed reduced levels of phosphorylated
JAK1, as well as STAT1, with no effect on the duration or
the steepness of the activation/inactivation phases (Fig. 5a,b).
These results suggest that the phospho-transfer function of the
mutant JAK1 was impaired, whereas the basal kinetics of
phosphorylation and dephosphorylation were normal.
We then studied if the mutant JAK1 affected phosphorylation
of the partner Janus kinases TYK2 and JAK2 after stimulation
with IFN-a and IFN-g, respectively. We found that in patient’s
ﬁbroblasts the amount of phosphorylated TYK2 was strongly
reduced, whereas the amount of phosphorylated JAK2 was only
slightly diminished (Fig. 6).
Table 1 | Immunological investigations.
Cell type/Ig class Patient (3 years 8
months)
Age-matched
control range
Patient
(10 years)
Age-matched
control range
Patient
(19 years)
Age-matched
control range
White cell count *26.8 109 l 1 5.0–15.0 109 l 1 4.95 109 l 1 4.5–13.5 109 l 1 7.8 109 l 1 4–11.9 109 l 1
Neutrophil count *17.78 109 l 1 1.0–8.5 109 l 1 2.47 109 l 1 1.8–8.0 109 l 1 4.9 109 l 1 2–7.5 109 l 1
Lymphocyte count 6.08 109 l 1 3.0–13.5 109 l 1 1.62 109 l 1 1.1–5.9 109 l 1 1.55 109 l 1 1–2.8 109 l 1
CD3þ T cells 49%,
3.0 109 l 1
39–73%,
1.8–8.0 109 l 1
*45%,
0.73 109 l 1
55–78%,
0.7–4.2 109 l 1
*29%,
*0.45 109 l 1
55–83%,
0.7–2.1 109 l 1
CD19þ B cells *45%,
2.7 109 l 1
17–41%,
0.6–3.1 109 l 1
*33%,
0.53 109 l 1
10–31%,
0.2–1.6 109 l 1
*40%,
0.62 109 l 1
6–19%,
0.1–0.5 109 l 1
CD16þCD56þ NK cells 3%,
0.2 109 l 1
3–16%,
0.1–1.4 109 l 1
20%,
0.32 109 l 1
4–26%,
0.09–0.9 109 l 1
28%,
0.43 109 l 1
7–13%,
0.09–0.6 109 l 1
CD3þCD4þ T cells 28%,
1.7 109 l 1
25–50%,
0.9–5.5 109 l 1
23%,
0.37 109 l 1
27–53%,
0.3–2.0 109 l 1
*16%,
*0.25 109 l 1
28–57%,
0.3–1.4 109 l 1
CD3þCD8þ T cells 23%,
1.4 109 l 1
11–32%,
0.4–2.3 109 l 1
16%,
0.26 109 l 1
19–34%,
0.3–1.8 109 l 1
12%,
*0.19 109 l 1
10–39%,
0.2–0.9 109 l 1
CD4þCD45RAþ T cells *12% 62–90 % 43%w 31–65%
CD8þCD45RAþ T cells *9% 46–85 % *24%w 42–73%
gdT-cell 2% o10%
IgG *38.8 g l 1 3.1–13.8 g l 1 *17.8 5.4–16.1 11.9 g l 1 6.0–16.0
IgA *1.8 g l 1 0.3–1.2 g l 1 1.00 0.7–2.5 0.9 g l 1 0.8–2.8
IgM 1.5 g l 1 0.5–2.2 g l 1 0.61 0.5–1.8 *0.45 g l 1 0.5–1.9
IgG1 *12.9 3.6–7.3
IgG2 *0.82 1.4–4.5
IgG3 0.77 0.3–1.1
PHA stimulationz 172 Z70 *12.6 Z70 *3.32 Z14.4
Candida stimulationz *17.6 Z26.8
PPD stimulationz *26.2 Z41.5
CD3 stimulationz *3.2 Z7.6
*Denotes an abnormal result.
wResults are shown for the CD45RAþCD27þ cells.
zT-cell stimulation index calculated as maximum stimulation value/background value.
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P733L has stronger effect on signalling than P832S. To study
effects of each of the two patient’s mutations separately,
we cloned the wild-type JAK1 (JAK1WT) and introduced P733L,
P832S or P733L/P832S mutations by site-directed mutagenesis.
We then expressed these constructs in the human ﬁbrosarcoma
U4A cells that lack endogenous JAK1 (ref. 23). The robustness of
this model relies on the fact that STAT1 and STAT2
phosphorylation after stimulation with interferons is totally
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Figure 2 | Impaired STATphosphorylation and cytokine responses in the patient’s blood cells. (a) Left panel. Numbers of cells positive for the presence
of phosphorylated STAT proteins were measured by FACS after 10min stimulation of whole blood of the patient (age 20 years) (open circles) and
compared with a healthy travel control tested under the same conditions (black dots). The assay was repeated either three times or six times (thrice on two
occasions, in which case two different travel controls were studied). Blue lines show geometric means. Unpaired two-tailed Student t-test with Welch’s
correction. Right panel. FACS gating for pSTAT1 after IFN-a and IFN-g stimulation is shown. (b–f) Cytokine responses measured after stimulation in whole
blood of the patient in independent assays (open circles) and compared with healthy controls tested under the same conditions (black dots). Numbers of
controls in different assays were: (b) LPS only n¼ 65, LPSþ IL-12 n¼40, LPSþ IFN-a n¼ 20, PHA only n¼60, PHAþ IL-12 n¼45, PHAþ IFN-a n¼ 20;
(c) PHA only n¼ 50, PHAþ IFN-a n¼ 20; (d–f) n¼ 30. Blue lines show geometric means. Two-tailed Mann–Whitney test.
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dependent on JAK1 and in U4A cells the signalling pathway
is rescued only upon re-expression of JAK1 (Fig. 7a,b)23,24.
We found that phosphorylation of JAK1P832S was similar to
that of JAK1WT, but phosphorylation of JAK1P733L/P832S was
completely abolished and that of JAK1P733L was either abolished
(Fig. 7a) or very strongly reduced (Fig. 7b), suggesting that
the amino-acid change P733L in the pseudokinase domain
impairs JAK1 function leading to the reduced phosphorylation
of tyrosines Y1034 and Y1035 in the activation loop of the kinase
domain (Fig. 7a,b). Nevertheless, all four JAK1 variants were able
to mediate STAT1 and STAT2 phosphorylation (Fig. 7a,b).
We then transduced primary patient ﬁbroblasts with lentiviral
vectors expressing the wild-type and mutant JAK1 proteins
(Fig. 7c). Forced expression of JAK1WT signiﬁcantly increased
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Figure 4 | Patient’s ﬁbroblasts show reduced induction of gene expression after IFN-a and IFN-c stimulation. Cells were stimulated with IFN-a for 15 h
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STAT1 phosphorylation after stimulation with IFN-a and IFN-g.
Forced expression of JAK1P832S rescued STAT1 phosphorylation
to a similar extent as JAK1WT, whereas expression of
the JAK1P733L or JAK1P733L/P832S proteins led to signiﬁcantly
reduced STAT1 phosphorylation. Taken together, these results
indicate that the double-mutant JAK1P733L/P832S protein
is functionally deﬁcient and that its defect is mostly caused by
the P733L mutation, whereas the contribution of P832S is
less pronounced.
JAK1 can mediate signalling independently of its phosphorylation.
It is known that overexpression of JAKs can lead to self-
phosphorylation and activation25. This explains the observation
that forced expression of JAK1WT or JAK1P832S in U4A cells
caused spontaneous self-phosphorylation of JAK1, as well as
phosphorylation of STAT1 and STAT2, even in the absence of
interferon stimulation (Fig. 7a,b). Unexpectedly we observed that
following interferon stimulation, JAK1P733L/P832S was able to
induce STAT1 and STAT2 phosphorylation even in the absence
of JAK1 phosphorylation (Fig. 7a,b). Similarly, JAK1WT and
JAK1P832S could induce STAT1 and STAT2 phosphorylation in a
dose-dependent manner in response to interferon stimulation,
despite the level of JAK1 phosphorylation remaining relatively
constant (Fig. 7a,b). These observations suggest that JAK1 has a
mode of function in interferon signalling that is independent of
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phosphorylation of tyrosines in its activation loop, for example,
providing a scaffold for the juxtaposed Janus kinase. This putative
JAK1 function could explain why such a profound defect in
JAK1 phosphorylation observed in the patient-derived ﬁbroblasts
leads to only modest reduction in the downstream STAT
phosphorylation (Figs 3 and 5).
JAK1 pseudokinase domain is essential in IFN-c signalling. To
further study this hypothesis and to identify the domain
responsible for kinase-independent JAK1 function, we cloned
a series of its superfolder green ﬂuorescent protein (sfGFP)-
tagged kinase-dead and deletion mutants (JAK1K908E, JAK1KinD,
JAK1CKinD, JAK1CKinD/K908E, JAK1KinD/CKinD; Supplementary
Fig. 4) and studied them alongside the patient mutation
(JAK1P733L/P832S). To ensure that the observed effects are not
artifacts of JAK1 activation due to massive overexpression
following cell transfection, we used JAK1-deﬁcient Flp-In
U4C cells26, which, similarly to U4A, lack endogenous expression
of JAK1, and generated cell clones that stably expressed our
mutant JAK1 constructs inserted in the FRT sites. First, we used
live imaging of these stable U4C cell clones to look at the
subcellular localisation of the sfGFP-tagged mutant JAK1
proteins. The wild type and mutant JAK1 proteins were all
similarly associated with cell membrane (Supplementary Fig. 5).
Following IFN-a and IFN-g stimulations, the phosphorylation of
JAK1P733L/P832S and JAK1K908E was reduced, and
phosphorylation of JAK1CKinD and JAK1CKinD/K908E was
abolished (Fig. 8). After IFN-a stimulation STAT1
phosphorylation was strongly reduced in cells expressing the
kinase-dead mutant JAK1K908E or the mutant JAK1KinD lacking
the kinase domain; however, it was only slightly reduced in these
cells after IFN-g stimulation (Fig. 8). Cells expressing the mutant
JAK1CKinD protein lacking the pseudokinase domain showed
strong reduction in phosphorylated STAT1 both after IFN-a and
IFN-g stimulations (Fig. 8). Complete abrogation of STAT1
phosphorylation was observed in cells expressing either
JAK1KinD/CKinD, which lacked both pseudokinase and kinase
domains, or JAK1CKinD/K908E, a kinase-dead mutant lacking also
the pseudokinase domain. Taken together, these data
demonstrate that JAK1 has a mode of function, which is
independent of its kinase activity and its phosphorylation in the
kinase domain, but requires the presence of its pseudokinase
domain. This JAK1 function was particularly clear after IFN-g
stimulation: in the absence of its kinase domain, JAK1 with the
functional pseudokinase domain can still transmit signalling after
IFN-g stimulation leading to STAT1 phosphorylation.
Discussion
Here, we describe JAK1 signalling disruptions in a patient
exhibiting PID. In immune cells JAK1 mediates intracellular
signalling from multiple cytokine receptors27. Therefore, it
seems likely that impaired phosphorylation of several STAT
proteins contributed to the immunodeﬁciency manifested by the
patient. Impaired responses to IL-2 may have led to progressive
T lymphopenia, whereas increased IL-6 production could have
been responsible for the persistent increased serum IgG levels.
JAK1-deﬁcient mice are runted at birth and have severely reduced
numbers of thymocytes, pre-B cells and mature T and
B lymphocytes28. Although JAK1-deﬁcient mice died
perinatally, the disease in our patient has been less severe,
probably because his JAK1 deﬁciency is partial and cells have
retained ability to mediate STAT signalling. Nevertheless, the
*
2FTGH U4A +
e.v.
U4A +
JAK1wt
U4A +
JAK1P733L/P832S
U4A +
JAK1P832S
U4A +
JAK1P733L
2FTGH U4A +
e.v.
U4A +
JAK1wt
JAK1wt
U4A +
JAK1P733L/P832S
U4A +
JAK1P832S
U4A +
JAK1P733L
JAK1P733L
JAK1
JAK1-sfGFP
* pJAK1
pJAK1
-sfGFP
0 10
0
10
0
10
0
10
0
10
0
10
00 0 1 10 0 1 10 0 1 10 0 1 10
pSTAT1
STAT1
pSTAT2
β-actin
STAT2
0.
06N
D
0.
94 1.
1
1.
2
0.
80
0.
81
0.
97 1.
0
N
D
N
D
N
D
N
D
N
D
N
D
N
D
N
D
N
D
N
D
1.
5
N
D
N
D
N
D 7.
8 1
1
1
1
1
3.
6
5.
5
0.
12
0.
24 1.
1
2.
6
0.
29 1.
2
2.
7
4.
5
1.
4
2.
2
4.
1
5.
5
0.
40 46 N
D
N
D 3.
2 11 17
0.
70 1.
7
4.
0
9.
0
0.
25 1.
0
2.
7 15
0.
59 4.
5 12 18
250 kDa
130 kDa
250 kDa
130 kDa
pJAK1/JAK1:
pSTAT1/STAT1:
pSTAT2/STAT2:
55 kDa
100 kDa
100 kDa
130 kDa
130 kDa
pSTAT1
0 05 0 5 0.
5
5 0 0.
5
5
STAT1
pJAK1
pJAK1
-sfGFP
β-actin
β-actin
JAK1
-sfGFPJAK1
pJAK1/JAK1: ND 0.5
9
1.
0
0.
94 1.
1
N
D
N
D
N
D
N
D
N
D
N
D
0.
06
0.
02
0.
02
0.
04 1.
5
1.
1
0.
96
0.
90
pSTAT1/STAT1: ND 29 ND ND 9.6 17 18 0.4
8
6.
4 14 16
0.
56 7.
6 18 20 2.
2 10 22 23
55 kDa
100 kDa
100 kDa
130 kDa
250 kDa
130 kDa 
250 kDa
pSTAT1
GFP
Mock
α γα γ α γ α γ α γ
N
D
0.
32 N
D
N
D 1
0.
36 N
D
0.
60
0.
24 1.
1
0.
31 N
D
0.
33
0.
10N
DpSTAT1/ACT:
55 kDa
100 kDa
37 kDa
IFN-α (ng ml–1): IFN-γ (ng ml–1): 0.0
5
0.
05
0 0.
5
50.
05
0 0.
5
50.
05
IFN -:
JAK1P733L/P832SJAK1P832S
a b
c
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patient exhibited clinically signiﬁcant susceptibility to atypical
mycobacteria. This could be explained by a combination of T-cell
lymphopenia, reduced IFN-g production by the existing T cells,
and impaired JAK1-STAT1 signalling downstream of the IFN-g
receptor. We found that hypomorphic JAK1 mutations
have pleiotropic effects and affect multiple signalling pathways.
Nevertheless, the disease manifested clinically with recurrent
atypical mycobacterial infection, which suggests a dominant
effect on the IFN-g pathway.
Non-hematopoietic malignancy at a young age was a notable
feature in our patient. Recently, somatic loss-of-function muta-
tions in JAK1 have been associated with gynaecologic cancers12.
Tumours also have been reported in patients with other defects in
the IL-12/IFN-g pathway, including Kaposi sarcoma29, B cell
lymphoma30, disseminated cutaneous squamous cell
carcinoma31, oesophageal squamous cell carcinoma32
and pineal germinoma33. These observations and the ﬁndings
reported here demonstrate that impaired IL-12/IFN-g signalling
predisposes not only to mycobacterial infection, but also
to malignancy, probably owing to impaired immune surveillance.
JAK1 inhibitors, for example, small molecule tofacitinib
that inhibits JAK1 and JAK3, are used for treatment of
rheumatoid arthritis and are currently tested in other
immunological disorders, such as psoriasis and inﬂammatory
bowel disease. Serious infections, including tuberculosis, and
cancers have been reported in tofacitinib clinical trials34–37. These
observations are in line with the clinical presentation of
our patient, highlighting the phenotype associated with JAK1
deﬁciency, either pharmacological or genetic.
Although the JAK-STAT pathway has been studied extensively,
the mechanism of JAK activation upon cytokine stimulation
is not entirely clear. JAKs are activated through cytokine-
induced trans-phosphorylation. It was shown that at the IL-2
receptor both JAK1 and JAK3 can trans-phosphorylate each
other without being phosphorylated themselves38. Our data
show that at the IFN-g receptor JAK1 can transmit signalling
even in the absence of its kinase domain, which precludes
phosphorylation of JAK2 by JAK1. Instead, our ﬁndings suggest
that JAK1 pseudokinase domain is required for interaction
with JAK2, and this interaction, rather than JAK1 kinase activity,
is mandatory for JAK2 activation after IFN-g stimulation leading
to STAT1 phosphorylation. In contrast, IFN-a signalling requires
the presence of both kinase and pseudokinase domains of
JAK1 (Fig. 8). This may be explained by hierarchical trans-
activation of JAKs, where upon IFN-a stimulation JAK1 ﬁrst
auto-phosphorylates and then phosphorylates TYK2, whereas
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upon IFN-g stimulation it is JAK2 that auto-phosphorylates
ﬁrst and then phosphorylates JAK1; hence, functional JAK1
deﬁciency markedly impairs TYK2 phosphorylation, but has no
strong effect on JAK2 phosphorylation (Fig. 6). This hierarchy is
consistent with previous observations that JAK2 phosphorylation
does not require active JAK1, whereas JAK1 activation requires
active JAK2 (ref. 39).
Although no full-length crystal structure of JAK1 or any
other Janus kinase is currently available, 2D electron microscopy
averages and 3D reconstructions show that JAK1 domains
have conformational ﬂexibility and that pseudokinase and kinase
domains are closely associated with each other40. In Janus kinases
the pseudokinase domain stabilises the inactive conformation of
the kinase domain41. In structural models of JAKs, many tumour-
associated activating mutations map to the interface between
the pseudokinase and kinase domains, presumably disrupting
interaction between them, which facilitates activation of
the kinase domain18,41. For example, an activating mutation
F734L in JAK1, found in a sample from a T-cell acute
lymphoblastic leukaemia patient42,43, maps in the b7–b8 loop
of the pseudokinase domain that interacts with the b2–b3 loop
of the kinase domain18,41. The P733L mutation that we found in
our patient maps in the same pseudokinase b7–b8 loop next
to F734L, however, as we have shown here, P733L reduces JAK1-
mediated signalling, suggesting that it may enhance auto-
inhibitory interaction between the pseudokinase and the kinase
domains.
In summary, hypomorphic recessive germline JAK1 mutations
that affect multiple signalling pathways were found in a PID
case that manifested with atypical mycobacterial infections and
increased susceptibility to cancer. This phenotype associated with
a long-term functional JAK1 deﬁciency predicts effects of
prolonged administration of JAK1 inhibitors. We also describe
a mechanism of JAK1 function in interferon signalling, which is
independent of phosphorylation of tyrosines in its activation loop
and its kinase function. These ﬁndings illustrate that discovery
of novel naturally occurring mutations can reveal the molecular
basis for human disorders, and also helps to understand
fundamental biological mechanisms, even in well-characterized
pathways such as the JAK-STAT pathway.
Methods
Ethics statement. Blood samples and skin biopsies were obtained with informed
consent from all subjects in accordance with the Declaration of Helsinki and with
approval from the ethics committee (NRES Committee London—Bloomsbury
06/Q0508/16).
Whole-exome sequencing. Library preparation, exome capture and sequencing
have been done according to the manufacturers’ instructions. For exome target
enrichment Agilent SureSelect 38Mb kit was used. Sequencing was done using
Illumina HiSeq with 94 bp paired-end reads. Reads from raw FASTQ ﬁles were
aligned to the hg19 reference genome using Novoalign version 2.08.03. Duplicate
reads were marked using Picard tools MarkDuplicates. Calling was performed
using the haplotype caller module of GATK (https://www.broadinstitute.org/gatk),
creating genomic variant call format (gVCF)-formatted ﬁles for each sample. The
individual gVCF ﬁles were combined into gVCF ﬁles containing 100 samples each.
The ﬁnal variant calling was performed using the GATK ‘GenotypegVCFs’ module
jointly for all cases and controls. Variants quality scores were then re-calibrated
according to GATK best practices separately for indels and SNPs. Resulting var-
iants were annotated using software ANNOVAR.
Sequence alignment and protein modelling. The known JAK1 protein sequences
from Ensembl (http://www.ensembl.org) were aligned using the Multiple Sequence
Alignment ClustalW2 (http://www.ebi.ac.uk/Tools/msa/clustalw2/). Modelling
of the pseudokinase (JH2) and kinase (JH1) domains of JAK1 was done by
I-TASSER44, using JAK1 sequence (AA 583–1153) and the three-dimensional
structure of TYK2 (PDB 4OLI) as a template. The model with the best
conﬁdence score (C-Score) was visualized by Visual Molecular Dynamics
software (http://www.ks.uiuc.edu/Research/vmd/).
Cells. Cell lines U4A and 2fTGH were kindly provided by Dr George Stark.
Flp-In U4C (U4C-FRT) cells were kindly provided by Dr Claude Haan. Lack of
JAK1 expression in JAK1-deﬁcient U4A and U4C cells has been veriﬁed by western
blotting. Cells were tested for mycoplasma contamination and were shown to be
mycoplasma-negative. The parental 2fTGH human ﬁbrosarcoma cell line and
U4A and U4C-FRT cell lines, patient and control ﬁbroblasts as well as 293T
cells were cultured in DMEM medium (E15–810,PAA) and 10% heat-inactivated
FCS fetal bovine serum (35 5500, Lot 001514, BD, Cowley, Oxford). Parental
Flp-In U4C (U4C-FRT) cells or JAK1-complented stable clones were kept in the
presence of 100 mgml 1 Zeocin (Invivogen) or 250mgml 1 Hygromycin B Gold
(Invivogen), respectively.
Determination of mRNA levels by relative real-time PCR. Total RNA
was extracted using RNAeasy Plus Mini kit (Qiagen) from ﬁbroblast left unsti-
mulated or stimulated with 1–100 ngml 1 IFN-a for 15 h or 0.01–1 ngml 1
IFN-g for 8 h. 0.3–1 mg RNAs were then reverse-transcribed with Oligo-dT using
RevertAid Reverse Transcriptase (ThermoFisher). For the determination of the
mRNA levels of the target genes, we performed qPCR using gene speciﬁc
primers (Supplementary Table 2) and KAPA SYBR FAST qPCR (KK4602,
Kapa biosystems). Fold changes were calculated using the DDCT method
against house-keeping genes.
Cloning, mutagenesis and transfection. For cloning purposes hJAK1 gene was
cloned into the vector pcDNA3.1 (þ ) (Invitrogen), used as a template for PCR and
subcloned into a pHR-Ub-Em vector (4), using standard cloning procedures.
Myc-tagged or sfGFP-tagged JAK1 constructs were subsequently cloned in
pcDNA6A-myc-His (ThermoFisher, ref. V22120). Cloning of JAK1-sfGFP cDNAs
in pcDNA5/FRT/TO (ThermoFisher, V652020) was performed via ApaI/KpnI sites
(JAK1-sfGFP in pcDNA6A as donor plasmids). The mutations P733L, P832S,
P733L/P832S and K908E were introduced using QuikChange Site-Directed
mutagenesis strategy. JAK1 deletion mutants JAK1CKinD (del aa. 583–855),
JAK1KinD (del aa. 875–1153) and JAK1CKinD/KinD (del aa. 583–1153) were
generated via Golden Gate assembly, with outward primers carrying BsmbI
(New England Biolabs) sites. Transient transfections of U4A cells were carried
out using Lipofectamine reagent (ThermoFisher), following manufacturer’s
instructions. Stable clones of complemented U4C-FRT were generated by
contrasfecting the proper JAK1-sfGFP in pcDNA5/FRT/TO construct along with
pOG44 (ThermoFisher), followed by selection in Hygromycin-containing medium.
The primers used in the cloning and mutagenesis are summarized in the
Supplementary Table 2. sfGFP is a genetically modiﬁed form of GFP with reduced
dimerisation properties in comparison with the wild-type GFP45.
Lentivirus preparation and transductions. The lentivirus stocks were prepared
by transient transfection of 293T cells (75 cm2 ﬂasks at 50% conﬂuency) with:
the envelope plasmid pMD.G (4 mg), the packing plasmid CMV8.91 (4 mg) and the
expression plasmid pHR-UbEm (6mg) along with 35 ml the transfection reagent
Transit 2020 (5454, Mirus) following the manufacture instructions. 24 h post
transfection (hpt) the media was replaced and medium was harvested at 48
and 72 h post transfection, pooled, cleared by low-speed centrifugation
(1,200 rpm, 5min), and ﬁltered through 0.45-mm-pore-size ﬁlters, and titered
by limited dilution scoring for eGFP-positive cells 3–5 days after infection.
Virus stocks were stored up to 3 weeks at 4 C for transduction experiments.
Transductions of patient ﬁbroblast and U4A cells were carried out by infection
at a multiplicity of infection of 1–3 in the presence of 8 mgml 1 of Polybrene
(107689, Sigma) overnight, then the virus containing media was replaced by
fresh media, samples were stimulated and harvested 2–5 days after infection.
Cells stimulations and immunoblotting. STATs’ phosphorylation was tested
in complemented U4A cells, U4C-FRT cells or patient ﬁbroblasts along with
appropriate control cells upon stimulation with IFN-a (11101–2, PBL) or IFN-g
(IF002, Millipore), in full growth medium at 37 C. Then, the cells were trypsinized,
washed and lysed in cold radioimmunoprecipitation assay buffer supplemented
with phosphatases (P5726, Sigma) and protease inhibitors (11836153001, Roche)
for 30min at 4 C. The lyses were then centrifuged at 10,000g for 10min at
4 C, the supernatants were quantiﬁed and 10–50 mg of total protein was separated
by 10% SDS-PAGE and analysed by western blot. Membranes were cut horizon-
tally according to molecular size markers, and stripes were incubated with
different Abs. Immunoblots were developed with the enhanced chemiluminescence
western blotting Reagent (Amersham). The following Abs were used: anti-JAK1
(610231, BD Biosciences; 1/1,000 dilution), anti-pJAK1 Tyr1022/1023 (3331, Cell
Signaling Technology; 1/1,000 dilution), anti-JAK2 (Clone D2E12, 3230, Cell
Signaling Technology; 1/1,000), anti-pJAK2 Tyr1007/1008 (Clone C80C, 33776,
Cell Signaling Technology; 1:1,000), anti-TYK2 (Clone D4I5T, 14193, Cell
Signaling Technology; 1:1,000), anti-pTYK2 Tyr1054/1055 (Clone C80C, 9321,
Cell Signaling Technology; 1:1,000), anti-STAT1 (9172, Cell Signaling
Technology; 1:1,000), anti-pSTAT1 Tyr701 (Clone 58D6, 9167, Cell
Signaling Technology; 1:1,000), anti-STAT2 (4594, Cell Signaling Technology;
1:1,000), anti-pSTAT2 Tyr689 (07–224, Millipore; 1:2,000), anti-b-Actin
(Clone AC-15, A5451, Sigma-Aldrich; 1:10,000), anti-GFP (11814460001,
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms13992
10 NATURE COMMUNICATIONS | 7:13992 | DOI: 10.1038/ncomms13992 | www.nature.com/naturecommunications
Roche or ab290, AbCam; 1:2,000) and anti-Myc (clone 9B11, 2276, Cell
Signaling Technology; 1:1,000). Band densitometry was determined by Image
Studio Lite (Licor). Fold changes of phospho/non-phosphorylated proteins were
calculated against the indicated internal reference sample. Similarly, JAK1
protein levels in primary ﬁbroblasts were determined after normalisation with
b-actin (loading control). Uncropped scans of western blots are shown in
Supplementary Fig. 11.
Microscopy. U4C cells complemented with sfGFP-tagged JAK1 mutants were
seeded at 50,000 cell per well on 24-well Sensoplates (662892, Greiner). Two
days later, living cells were rinsed twice in 1xPBS and imaged in Live Cell Imaging
Solution (A14291DJ, ThermoFisher). Nuclei were stained with NucBlue reagent
(R37605, ThermoFisher). Micrographs were acquired at a Leica SP5 confocal
microscope.
FACS analysis of STAT phosphorylation. Blood was collected in EDTA. In total,
100ml of blood was left unstimulated and 100ml was stimulated with indicated
cytokines for 10min (IL-2, Chiron, 105Uml 1; IL-4, ImmunoTools, 1 mgml 1;
IL-6, R&D systems, Abingdon, England, 100 ngml 1; IL-10, R&D systems,
500 ngml 1; IFNg, R&D systems, 200 ngml 1; IFNa, PBL Interferon Source,
106 Uml 1; IL-27, R&D systems, 500 ngml 1). Red cells were lysed and
phosphorylation state ﬁxed using Lyse/Fix (BD Biosciences). Cells were permea-
bilised with Perm Buffer III (BD Biosciences) before being stained with 5 ml surface
antibodies: APC Anti-CD3 1:20 dilution, or PerCP Anti-CD4 1:20, and PE anti-
STAT1 (p701) 1:20, or Alexa Fluor 488 Anti-STAT5 (Y694) 1:20, or Alexa Fluor
488 Anti-STAT4 (Y693) 1:20, or Alexa Fluor 488 Anti-STAT3 (49/STAT3) 1:20, or
Alexa Fluor 488 Anti-STAT6 (Y641) 1:20 (all from BD Biosciences). Gating was
done on the following lymphocyte populations: total lymphocytes for the analysis
of STAT1 phosphorylation after IFN-a stimulation; CD3- lymphocytes for the
analysis of STAT1 phosphorylation after IFN-g stimulation and of STAT3
phosphorylation after IL-10 or IL-6 stimulations; CD3þ lymphocytes for the
analysis of STAT4 phosphorylation after IFN-a stimulation, of STAT5 phos-
phorylation after IL-2 stimulation and of STAT6 phosphorylation after
IL-4 stimulation; CD4þ lymphocytes for the analysis of STAT1 phosphorylation
after IL-27 stimulation. The stained cells were detected using a FACsCalibur
(BD Biosciences); 10,000 gated events were collected. Analysis was performed using
CellQuest software (Becton Dickinson).
Whole-blood cytokine production assays. Whole blood was diluted 1:5 in RPMI
into 96-well F plates (Corning) and activated by single stimulation with IL-12
(20 ngml 1; R&D Systems), PHA (10mgml 1; Sigma-Aldrich), LPS (1 mgml 1)
List Biochemicals, IFN-g (2 10 IUml 1, Imukin, Boehringer Ingelheim), IFN-a
(2 103 IUml 1, Intron A, Schering Plough, UK) or using co-stimulations as
indicated. Supernatants were taken at 24 h. Cytokines were measured using
standard ELISA according to the manufacturer’s recommendations (IFN-g,
Pelikine, Sanquin, NL), or multiplexed (TNFa, IL-12, IL-10, IL-6, RþD Systems
Fluorokinemap) on a Luminex analyser (Bio-Plex, Bio-Rad, UK). Data were
statistically analysed by the two-tailed Mann–Whitney test using Prism 6
(GraphPad Software).
Data availability. The data that support the ﬁndings of this study are available
from the corresponding author upon request.
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